Regeneron Pharmaceuticals, Inc.
Close on Nov 18, 2026Market cap $97.81BP/E 20.9Yield –
Regeneron Pharmaceuticals Trade Accounts Receivable, Net by Quarter
Trade Accounts Receivable, Net ($M) ($M)
Regeneron Pharmaceuticals Trade Accounts Receivable, Net: $4,132M in Q3 2026, up 19.0% from a year earlier.
Where the Q3 2026 figure comes from
Source: Form 10-Q (filed 2026-10-30) ↗
Reported in Form 10-Q / 10-K Consolidated Balance Sheets (XBRL).
quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Trade Accounts Receivable, Net ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q3 2026 | Sep 30, 2026 | 4,132 | +19.0% | Form 10-Q (filed 2026-10-30) ↗ |
| Q2 2026 | Jun 30, 2026 | 3,784 | +5.7% | Form 10-Q (filed 2026-07-30) ↗ |
| Q1 2026 | Mar 31, 2026 | 3,529 | -6.1% | Form 10-Q (filed 2026-04-29) ↗ |
| Q4 2025 | Dec 31, 2025 | 3,458 | -19.2% | Form 10-Q (filed 2026-10-30) ↗ |
| Q3 2025 | Sep 30, 2025 | 3,471 | -16.2% | Form 10-Q (filed 2025-10-28) ↗ |
| Q2 2025 | Jun 30, 2025 | 3,581 | -9.5% | Form 10-Q (filed 2025-08-01) ↗ |
| Q1 2025 | Mar 31, 2025 | 3,760 | +0.6% | Form 10-Q (filed 2025-04-29) ↗ |
| Q4 2024 | Dec 31, 2024 | 4,278 | +10.0% | Form 10-K (filed 2026-02-04) ↗ |
| Q3 2024 | Sep 30, 2024 | 4,142 | +9.2% | Form 10-Q (filed 2024-10-31) ↗ |
| Q2 2024 | Jun 30, 2024 | 3,958 | +6.5% | Form 10-Q (filed 2024-08-01) ↗ |
| Q1 2024 | Mar 31, 2024 | 3,739 | +4.5% | Form 10-Q (filed 2024-05-02) ↗ |
| Q4 2023 | Dec 31, 2023 | 3,888 | +8.4% | Form 10-K (filed 2025-02-05) ↗ |
| Q3 2023 | Sep 30, 2023 | 3,792 | -11.2% | Form 10-Q (filed 2023-11-02) ↗ |
| Q2 2023 | Jun 30, 2023 | 3,718 | -4.4% | Form 10-Q (filed 2023-08-03) ↗ |
| Q1 2023 | Mar 31, 2023 | 3,578 | -2.3% | Form 10-Q (filed 2023-05-04) ↗ |
| Q4 2022 | Dec 31, 2022 | 3,586 | -29.1% | Form 10-K (filed 2024-02-05) ↗ |
| Q3 2022 | Sep 30, 2022 | 4,268 | +4.5% | Form 10-Q (filed 2022-11-03) ↗ |
| Q2 2022 | Jun 30, 2022 | 3,888 | -33.9% | Form 10-Q (filed 2022-08-03) ↗ |
| Q1 2022 | Mar 31, 2022 | 3,664 | +15.5% | Form 10-Q (filed 2022-05-04) ↗ |
| Q4 2021 | Dec 31, 2021 | 5,059 | +62.6% | Form 10-K (filed 2023-02-06) ↗ |
| Q3 2021 | Sep 30, 2021 | 4,086 | – | Form 10-Q (filed 2021-11-04) ↗ |
| Q2 2021 | Jun 30, 2021 | 5,881 | – | Form 10-Q (filed 2021-08-05) ↗ |
| Q1 2021 | Mar 31, 2021 | 3,173 | – | Form 10-Q (filed 2021-05-06) ↗ |
| Q4 2020 | Dec 31, 2020 | 3,112 | – | Form 10-K (filed 2022-02-07) ↗ |
Cite this data
StockData. (2026). Regeneron Pharmaceuticals Trade Accounts Receivable, Net ($M), quarterly Q4 2020–Q3 2026 [Data set]. Compiled from Regeneron Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/regn/kpis/ar-trade
See every metric in the Regeneron Pharmaceuticals KPI table. Data updated Nov 4, 2026.
See a number that looks wrong?